FDA Approves ROMIDEPSIN — Amneal Pharmaceuticals LLC

# FDA Approves Generic Romidepsin from Amneal Pharmaceuticals Amneal Pharmaceuticals LLC has received FDA approval for generic romidepsin intravenous formulation, expanding the competitive landscape for this histone deacetylase inhibitor used in cutaneous T-cell lymphoma treatment. The approval is expected to increase pricing pressure on the branded product while potentially improving patient access to the therapy through lower-cost alternatives.